purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation acb earnings call period ending december image source motley fool aurora cannabis acb q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorgreetings welcome aurora cannabis third quarter result conference call participant listenonly mode questionandanswer session follow formal presentation conference call recorded today thursday february would like turn conference host ananth krishnan vice president corporate development strategy please go aheadananth krishnan vice president corporate development strategy thank operator hello everyone thank joining u today line miguel martin ceo glen ibbott cfo morning aurora issued news release announcing fiscal third quarter financial result separate news release announcing acquisition medreleaf australia separate news release fiscal q financial statement mda available ir website also accessed sedar edgar addition find supplemental information deck ir website listener reminded certain matter today conference call could constitute forwardlooking statement subject risk uncertainty related future financial business performance actual result could differ materially anticipated forwardlooking statementsshould invest aurora cannabis right buy stock aurora cannabis consider motley fool stock advisor analyst team identified believe best stock investor buy aurora cannabis one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return february risk factor may affect actual result detailed annual information form periodic filing registration statement document may similarly accessed via sedar edgar following prepared remark miguel glen conduct questionandanswer session covering analyst turn call miguel please go ahead miguel martin chief executive officer thank ananth quarterly performance demonstrated strength aurora business model built primarily upon global leadership high margin medical cannabis also financial discipline highlight include first strong revenue million several percentage point inclusive growth international medical cannabis segment second industry leading adjusted gross margin also year ago period third record adjusted ebitda representing fifth consecutive quarter positive adjusted ebitda fourth recall also one strongest balance sheet canadian lp global cannabis business debt free later month item move u closer toward goal generating positive free cash flow calendar delving q greater detail first want review announcement today regarding acquisition remaining equity interest medreleaf australia award currently leading distributor medical cannabis product australia company acquired total enterprise value million million paid cash remainder satisfied issuance aurora share transaction thoughtfully structured preserve strength aurora balance sheet represents strategic milestone aurora global cannabis leadership become largest platform nationally legal cannabis industry world acquiring medreleaf australia position u deliver doubledigit increase profitability australian business model higher revenue contribution higher gross margin aligns business key profitable international market notably germany poland youk immediately accretive adjusted ebitda accelerates path positive free cash flow generation end calendar year first partnered medreleaf australia back since time active contributor growth leveraging pharmaceutical grade cultivation science driven approach product innovation like germany australian market characterized clinicianled traditional pharma like product distribution model closely aligns aurora operational success high regulatory standard therapeutic good authority make australia challenging market new entrant providing advantage company like aurora able meet medreleaf australia already hold position medical cannabis australia already invested clinician education leveraging aurora comprehensive product portfolio provide bestinclass medicine support rapidly growing patient base extremely excited opportunity within rapidly growing aud million market would make largest medical market world outside north america welcome medreleaf australia fully aurora fold know able great thing together let u look deeply business canada maintained position medical market continue grow market share broad attractive product assortment positive sale mix importantly product innovation amid continuous disruption market know commitment launching steady stream exciting new product critical hold growing domestic medical share next generation cultivar often made available across europe australia providing patient highest potency appealing offering international market course ability offer pharma grade product global patient made possible competitive advantage built production network indoor eu gmp certified facility managed team deep experience pharmaceutical production already discussed australia earlier delve european operation generated sale record seven european country germany poland youk france switzerland malta czech republic germany largest european market operating since one three company domestic production facility market share flower according latest data market share selfpayers also three top cultivar country volume sale supportive legislative process moving toward descheduling medical cannabis potential wider legalization adult use cannabis supportive effort uniquely well positioned benefit supplier flower patient outside public insurance system poland second largest european market aurora earned cultivar market position volume excited opportunity growing market present youk patient responding favorably launch next generation cultivar led significant increase sale q compared q switzerland building successful launch q becoming trusted favorite patient currently widening distribution channel country allinall medical cannabis adjusted gross margin remained strong benefit sustainable cost reduction improved efficiency production operation turning back canada decision strategically allocate product higher margin medical market resulted modest expected yearoveryear revenue decline consumer cannabis system still adjusted gross margin improved substantially versus year ago period higher efficiency production operation favorable product mix finally exhibited inherent benefit diversified model expanding reach controlled environment agricultural industry vivo team currently leveraging cannabis facility move profitable cultivated orchard market current vegetable plant propagation business already generates steady predictable financial performance albeit seasonal cadence upcoming two three year think shareholder benefiting value creation coming segment expect acceleration vivos business plan continue drive revenue ebitda growth strategic progress past year move u toward goal positive free cash flow calendar would like turn call glen detailed financial overviewglen ibbott chief financial officer thank miguel good morning everyone q representative success executing business transformation tangible positive result brought company cash balance million quarter close later month repay remaining convertible senior note cash approximately million completes repayment nearly million debt last three year leave cannabis business debtfree looking q big picture delivered revenue growth comparable year ago period including significant increase sale high margin global medical cannabis segment profitability consolidated adjusted gross margin rose adjusted ebitda rose record million reflecting million improvement last year highest quarterly result adjusted ebitda q also marked fifth consecutive quarter positive adjusted ebitda let u go greater depth result q net revenue rose million million million year ago period overall medical cannabis generated million net revenue million compared last year segment international medical revenue million last year canadian medical cannabis million year year performance medical channel largely due positive market reaction canadian growing high potency cultivar key european market continued rapid growth australian medical market adjusted gross margin medical cannabis q versus year ago period consistently high margin result sustainable cost reduction improved efficiency production operation shift supply europe canada impact closing nordic production facility begin flow financials usual driven focus leadership global medical market medical cannabis represented total cannabis adjusted gross profit dollar increased million q compared million year ago period consumer cannabis net revenue million million year ago change expected result decision reallocate product higher margin market adjusted gross margin consumer cannabis compared prior year period significant increase margin coming higher cultivar yield continued efficiency improvement production driving lower unit cost plant propagation revenue million grew million year ago period recall seasonality business delivers higher revenue late winter spring month result revenue ebitda first half calendar year fiscal q q period plant propagation adjusted gross margin year ago period increase due product mix vegetable ornamental plant sale consolidated adjusted sga well controlled approximately million continues reflect ongoing commitment keeping sga million current business turning cash flow made significant progress q toward goal positive free cash flow calendar year remain firmly track achieve goal operation used million quarter inclusive working capital investment sequentially million considerably million used year ago period planned target million annualized expense reduction realized mainly q q driven continued operational efficiency initiative including shutdown nordic production site sale dutch asset remaining expense reduction flowing q manage working capital company shift forward growth opportunity successful balancing working capital need investing growth executing disciplined financial management capex invested approximately million quarter split evenly maintenance growth initiative looking forward next quarter fiscal q canadian medical consumer segment expected steady quarter quarter europe australia provide growth region acquisition medreleaf australia provide incremental revenue gram cannabis sold delivered commensurate improvement gross margin region q next fiscal year expect three global medical region canada europe australia delivering adjusted gross margin exceed target plant propagation expect see seasonally higher revenue gross profit would line historical performance comparable prior year period revenue growth combined ongoing cost control expected result continued positive adjusted ebitda q wrap strengthened financial condition due entirely commitment operational excellence strategic focus team positioning diversified global cannabis business deliver dependable revenue growth long term thanks much interest turn call back miguelmiguel martin chief executive officer thanks glen one takeaway investor would strategically financially best shape ever thanks team accomplishing set fully intend make good commitment top line growth continued sustainable adjusted ebitda generation million cash hand strong position work toward goal generating positive free cash flow calendar year operator please open line question question answer operatorthank conducting questionandanswer session operator instruction first question come frederico gomes atb capital market please proceedfrederico gomes atb capital market analyst hi good morning thank taking question first question acquisition australia mentioned market worth aud million rapidly growing give u idea fast market growing driver behind growth well sort asset place acquisition opportunity australia represents thank youmiguel martin chief executive officer got well good morning fred yeah listen incredibly excited acquisition said comment business partnering since great operator expharmacists wonderful piece business first foremost aud million year australian revenue market sizing coming report published penington institute really leveraged number unit sold represented reported tga key regulatory unit multiply average selling price per unit listen nielsen iri key piece tga primary regulatory body australia one publish unit sold six month basis term growth look back market size estimated aud million grew firstsix month seen steady growth number approval key indicator prescription also continues grow first half saw close new approval represents significant increase since july say compare say canada seen improvement significant growth piece company buying market market data come different data source called noster data australia leading pharmacy data partner important know representative sample pharmacy signed great success market multiple brand really excited mentioned tga done wonderful job regulatory forward science based think market clearly advantage regulatory forward tga approved supplier thrilled foothold great acquisition margin accretive day one key marketfrederico gomes atb capital market analyst thank color second question germany done vote expected soon curious think deal pass think could impact medical market opportunity germany thank youmiguel martin chief executive officer yeah appreciate germany obviously key market u said one three company domestic production significant advantage hopeful going hear something late spring particularly around descheduling removal cannabis narcotic designation massive impact market allow pharmacist prescribe well patient greater access product actual timing going manifest see regulation supportive though action found german regulator whether approval process testing process certification process done really good job thing take time think legislation going really significant impact company like u participate medical portion obviously tag along impact see market around poland czech republic france others look momentum build momentum particularly part world thrilled progress looking forward seeing regulation come outfrederico gomes atb capital market analyst thank muchmiguel martin chief executive officer welcome fred appreciate itoperatorour next question come matt bottomley canaccord please proceedmatt bottomley canaccord genuity analyst hi good morning everyone thanks color far wanted pivot back domestically canadian medical side thing something get talked lot general given pretty immaterial portion lp strategy point seems like million quarter million revenue business time wondering maybe explain give color dynamic overall market tam medical slowly shrinking given retail hard find particularly province like ontario strategy maybe order increase share whether lp kind closing shop strategic initiative order get increased registration auroramiguel martin chief executive officer well matt good morning listen great question think two part question let take question laid add little bit yes believe roughly million year canadian revenue declining slightly able offset growing market share said think opportunity grow pie impact initially due growth rec business availability rec product impact reimbursement aspect would get recreational environment see patient system particularly veteran patient getting great value great service would get rec business mostly reimbursed model secondly see opportunity canadian medical business grow seeing interest union sort entity looking cannabis benefit getting bigger mention starting see clinical trial traditional medical establishment work cannabinoids would open today canadian adult population aiming medical cannabis system plenty opportunity medical cannabis business highest margin portion cannabis globally incredibly compelling piece thing important understand excellence canada critical federal legal medical cannabis market allows learn become adept navigating federally legal cannabis market largest leadership germany poland key market come directly learned canada able leverage similar product similar execution world class production canada shipping eu gmp product around world listen thrilled leadership canadian market canadian medical cannabis company clearly get great advantage leveraging exact system around worldmatt bottomley canaccord genuity analyst great appreciate one general sort philosophy strategy kind look number international market wondering term timing allocation deployment capital dollar certain market particularly europe key thing maybe look one yous counterpart earlier week announced deal poland know poland market guy talked little bit think mentioned huge amount investment lag time getting product registered get market obviously benefit term first mover thing look scarcity license overall regulatory landscape respect thing written versus timing expect maybe market launch something get talked lot sector think lot investor le seen get kicked road market outside yous canada actually really started gain accelerationmiguel martin chief executive officer yeah great question think one spend lot time would argue one best pretty significant modeling work done market also spend significant amount money local market people local market particularly grga side would tell boil calculation really based three core segment first assessment regulatory environment going sciencebased going eu gmp testing system going registration system going mentioned found market like germany like poland like lot market rigorous process science based testing formal case take longer people would like usually go backwards predictability term investment second aspect would size opportunity going selfpayer going reimbursed size population overall economics allow u make thoughtful investment thesis going go third going play market demonstrated great flexibility whereas market manufacturer wholesaler sale organization market manufacturer partner worldclass wholesaler sale organization think done excellent job mentioned one benefit seeing company particularly aurora successful market unlike say canada usually top five company account twothirds threequarters overall business european market whereas canada might take company benefit said execution infrastructure eugmp product gr registration work science side allows u sell product poland germany youk develop great efficiency u difficult something spend lot time definitely paid dividend u see resultsmatt bottomley canaccord genuity analyst ok great get back queue appreciate detail miguelmiguel martin chief executive officer got thank youoperatorour next question come tamy chen bmo capital market please proceedtamy chen bmo capital market analyst great thanks first question going back australia miguel talked number approval continues grow significant increase compared wanted revisit part like really caused australian market experience rapid growth like see medical market legalize growth significant like regulatory change last year really increased yeah increased acceptance medical cannabis among physician curious driving quite rapid growthmiguel martin chief executive officer yeah tamy great question think would tell probably three key aspect first tga primary regulatory agency done exceptional job rolling regulation easier step process mean process physician clinician sign prescribing physician ease pharmacy registered allowed service patient patient ability register mentioned large reimbursed market economics work well compassionate care program economically challenged access medical cannabis would first part second part also thoughtful local level sometimes tension federal legalization happens state level seen australia seen specific sort cadence move forward think third culturally cannabis accepted market think company operated done really good job seen consolidation market share largest market share company market share low one right u think come together unlike market seen tga rigorous authorization review acceptable product think continue market advantage company type rigor production certification happening absence format see larger market particularly ingestibles vapor product coming online grow overall market excited part world sort important piece really really excited acquisitiontamy chen bmo capital market analyst great helpful sticking curious understand timing acquiring rest stake medreleaf australia seen market experience tremendous growth felt like right time lastly say business middle east australia higher gross margin current international business thanksmiguel martin chief executive officer yeah let take second one first take first one currently supplier manufacturer medreleaf australia sale organization clinic connection organization margin lower statement upon acquisition would similar margin standpoint market say western europe eastern europe highest margin see cannabis globally margin today low term would say couple thing one talked earlier mentioned earlier analysis regulation market size ability sort leverage felt inflection point size market regulation ability leverage innovation new format coming clearly side owner business also aligned right time say great thing done build business like said founder expharmacist team done superb job building business collectively thought right time take next step product online able leverage australia cash position everything else going collectively aurora management well ownership medreleaf australia felt exactly right time u think deal happentamy chen bmo capital market analyst ok great thank youmiguel martin chief executive officer welcomeoperatorour next question come doug miehm rbc capital market please proceeddoug miehm rbc capital market analyst yeah good morning question capital allocation look australian acquisition amount cash used versus share issued walk decision making process decided needed much dilution relative million million paid especially given balance sheet much better cusp turning free cash flow positive thank youmiguel martin chief executive officer sure well dough make couple comment low glen get think worked incredibly hard take almost billion convertible debt really want demonstrate company incredibly thoughtful financial decision make going come expense growth opinion right allocation use amount stock versus amount cash order retain maximum flexibility cash position think understand point dilution think shareholder standpoint look valuation look trailing month revenue december aud million fact accretive day one believe right allocation deal going forward listen understand question allinall look free cash flow positive end year roughly million cash hand debt cannabis business piece coming online may large canada would make largest federally legal medical cannibal market world feel really good structure deal glen anything want add allocation thereglen ibbott chief financial officer pretty thorough miguel doug note consistent messaging last couple year share issuance really tried refocus incremental accretive new business strategic focus opposed back number year ago number cannabis company used fund operation funding operation adding incremental revenue margin miguel talked accretive value quite compelling strategic reason miguel laid see share valuable tool looking strategically part thinking well consistent full view market last couple year reserve share fordoug miehm rbc capital market analyst ok helpful maybe followup given group going reasonable sized shareholder company would expect long term shareholder companymiguel martin chief executive officer know mean going shareholder would hope everybody would longterm shareholder company decision think bearing term run company deal anything going forwarddoug miehm rbc capital market analyst ok great thank youmiguel martin chief executive officer got thank youoperatorour next question come pablo zuanic zuanic associate please proceedpablo zuanic zuanic associate analyst good morning everyone miguel thinking potential acquisition need make germany following australia maybe explain difference ontheground business model case australia shipping canada right pretty much medreleaf australia taking care everything else case germany seems asset ground foot ground change narcotic law change think need make acquisition germany pretty much investing already thanksmiguel martin chief executive officer got mean pablo think australia found great partner comfortable going way obviously impacted margin manufacturer thus trigger buy rest could experience margin see part world germany different obviously covering u early go back three criterion got comfortable regulator regulatory process got comfortable size market fact going reimbursed market also large selfpayer also got comfortable unique proposition offered incountry manufacturing aligned government first mover status reason right quite significant amount headcount infrastructure berlin sale marketing finance back office importantly government relation work well production team leuna think show flexibility go east look country like poland got sale marketing poland production poland bring product efficient way new genetics coming canada look say market like czech republic work partner thing switzerland austria think flexible core product patient clinician want able incredibly efficiently canada market get going continue make investment thrilled opportunity completely integrated australia look lot like germanypablo zuanic zuanic associate analyst right quick followup use australia production company acquired something would look road especially see case israel dumping claim market israel shutting every risk australia would need local production expand argument made various trend australia player thanksmiguel martin chief executive officer sure would happy israel shipped israel year production well know part world found really important environment allow importation registered certified product case eu gmp australia thoughtful registration process certification process worked economics efficiency able centralized place like canada incredible place u grow leverage genetics process low energy cost production cost ship around world significant advantage u heard anything australia none market would restrict ability canadian grown eu gmp tga authorized flower come market found something locally market got long history managing variety different facility definitely could seen australia term point restriction tga primary regulatory authority australia incredibly rigorous allow first foremost registration process rigorous requirement consistent see europe take anywhere eight month month every new product brought review testing reviewing actual coas certificate assurance key product vigilance precision production review every aspect labeling packaging well certification wholesale delivery pharmacy high bar see concentration think going see action australia maybe seen market reason see good margin excited love working tga like said people get little frustrated pace sometimes progress great market like australia germany others go backwards important asset allocation think excited think well therepablo zuanic zuanic associate analyst right thank youmiguel martin chief executive officer welcome pablooperatorthis concludes questionandanswer session would like turn floor back miguel martin closing commentsmiguel martin chief executive officer well first foremost thank everybody interest aurora excited said earlier never better shape today great day announce progress made core business importantly announced acquisition great asset one fastestgrowing largest medical cannabis market world continue believe medical cannabis best place cannabis globally demonstrated leadership thank everybody look forward speaking soon best byeoperatoroperator signoff duration minutescall participantsananth krishnan vice president corporate development strategymiguel martin chief executive officerglen ibbott chief financial officerfrederico gomes atb capital market analystmatt bottomley canaccord genuity analysttamy chen bmo capital market analystdoug miehm rbc capital market analystpablo zuanic zuanic associate analyst acb analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy